Table S2 shows the high expression of HMGB1 with poor prognosis of OS, FP, and PPS, especially for LUAD. The dataset of the GEPIA2 project indicates a statistical association between highly expressed HMGB1 and poor OS. We found that high HMGB1 expression is associated with poor clinical survival in terms of OS, PFS and PPS in ovarian cancer (Table S3). We also obtained an association between the high expression of HMGB1 and poor prognosis in terms of OS, DMFS and RFS, particularly focused on BRCA patients with HER2-positive status (Table S1). Here, ERBB2 is linked to ovarian carcinoma.